

Boston Biochem Incorporated

[View the current Boston Biochem Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bioporcorate/2101-Boston+Biochem+Incorporated.html)

(<http://www.bioportfolio.com/bioporcorate/2101-Boston+Biochem+Incorporated.html>)

Contact Details:

One Kendall Square, Building. 600
Cambridge
MA
02139
United States of America

Tel: 617-241-7072
Fax: 617-492-3565
Email: rbrace@bostonbiochem.com

Boston Biochem is the world's leading producer of high quality specialized reagents for the Ubiquitin Proteasome Pathway. These products include enzymes, substrates, inhibitors, ubiquitin derivatives and assay kits.

We also offer comprehensive custom services in the areas of protein purification, fermentation, protein expression optimization, protein conjugation and chemical synthesis.

Press Releases on Boston Biochem Incorporated:

[ASH Honors Rep. Doris O. Matsui \(D-CA\) and Melanie Bloom for Their Public Service, Leadership, and Commitment to Biomedical Research](#)

25th November, 2009

American Society of Hematology

WASHINGTON, Nov. 25 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest professional society of blood specialists, will recognize a member of the U.S. House

[iThemba Pharmaceuticals \(Pty\) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering](#)

25th November, 2009

DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals' service division and Pyxis Discovery announced today that they have signed a collaborative agreement

[Reportlinker Adds Blood Banking and Blood Products - Global Market Perspective](#)

25th November, 2009
Reportlinker

NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Blood Banking and Blood Products - Global Market Perspective <http://www>

[FDA Accepts Once Daily 23 mg Aricept\(R\) Extended Release NDA for Review](#)

24th November, 2009
Eisai Inc.

WOODCLIFF LAKE, N.J. and NEW YORK, Nov. 24 /PRNewswire/ -- Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug MADISON, N.J., Nov. 24

[Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference](#)

24th November, 2009
Quest Diagnostics

/PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is

BioNews Results for Boston Biochem Incorporated



- [Updates for SunLink \(NYSE:SSY\), Enzo Biochem Inc. \(NYSE:ENZ\), Pro-Pharmaceuticals \(OTC:PRWP\) California Chronicle: Nov 17 2009 2:50AM Matching: boston biochem](#)
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone \(HE3235\) at Genetic Engineering News: Nov 17 2009 10:24PM Matching: boston biochem](#)
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies Of Apoptone \(HE3235\) At AACR Molecular Targets And Cancer Therapeutics Conference Pharmaceutical Online: Nov 17 2009 12:08PM Matching: boston biochem](#)
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone \(HE3235\) at Montana's News Station: Nov 17 2009 7:24AM Matching: boston biochem](#)
- [Updates for SunLink \(NYSE:SSY\), Enzo Biochem Inc. \(NYSE:ENZ\), Pro-Pharmaceuticals \(OTC:PRWP\) Los Angeles Chronicle: Nov 16 2009 10:26AM Matching: boston biochem](#)
- [Updates for SunLink \(NYSE:SSY\), Enzo Biochem Inc. \(NYSE:ENZ\), Pro-Pharmaceuticals \(OTC:PRWP\) American Chronicle: Nov 16 2009 12:50AM Matching: boston biochem](#)
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone \(HE3235\) at AACR Molecular Targets and Cancer Thera Yahoo! Canada: Nov 16 2009 3:40PM Matching: boston biochem](#)
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone \(HE3235\) at KLFY: Nov 16 2009 3:27PM Matching: boston biochem](#)
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone \(HE3235\) at AACR Molecular Targets and Cancer Therapeutics Conference Red Orbit: Nov 16 2009 3:22PM Matching: boston biochem](#)

- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone \(HE3235\) at AACR Molecular Targets and Cancer Therapeutics Conference](#)
Red Orbit: Nov 16 2009 3:21PM Matching: boston biochem
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone \(HE3235\) at](#)
Baltimore Business Journal: Nov 16 2009 2:57PM Matching: boston biochem
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone \(HE3235\) at](#)
Charlotte Business Journal: Nov 16 2009 2:46PM Matching: boston biochem
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone \(HE3235\) at AACR Molecular Targets and Cancer Therapeutics Conference](#)
PR Newswire via Yahoo!: Nov 16 2009 2:43PM Matching: boston biochem
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone \(HE3235\) at](#)
Pacific Business News: Nov 16 2009 2:43PM Matching: boston biochem
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone \(HE3235\) at AACR Molecular Targets and Cancer Therapeutics Conference](#)
PR Newswire via Yahoo!: Nov 16 2009 2:43PM Matching: boston biochem

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

